Analytical Data
-
基因名
UNC45B
- Application
-
别名
Cardiomyopathy associated 4; CMYA4; FLJ38610; MGC119540; MGC119541; OTTHUMP00000163855; Protein unc 45 homolog B; Protein unc-45 homolog B; SMUNC45; Striated muscle UNC45; UN45B_HUMAN; Unc 45 homolog B (C. elegans); Unc 45 homolog B; UNC 45B; UNC-45B; UNC45; UNC45B
-
种属
Human
-
表达系统
E. coli
-
标签
GST-tag at N-terminal
-
纯度
Greater than 90% as determined by SDS-PAGE.
-
蛋白编号
Q8IWX7
-
表达区间
1-944 aa
-
氨基酸序列
MTVSGPGTPEPRPATPGASSVEQLRKEGNELFKCGDYGGALAAYTQALGLDATPQDQAVLHRNRAACHLKLEDYDKAETEASKAIEKDGGDVKALYRRSQALEKLGRLDQAVLDLQRCVSLEPKNKVFQEALRNIGGQIQEKVRYMSSTDAKVEQMFQILLDPEEKGTEKKQKASQNLVVLAREDAGAEKIFRSNGVQLLQRLLDMGETDLMLAALRTLVGICSEHQSRTVATLSILGTRRVVSILGVESQAVSLAACHLLQVMFDALKEGVKKGFRGKEGAIIVDPARELKVLISNLLDLLTEVGVSGQGRDNALTLLIKAVPRKSLKDPNNSLTLWVIDQGLKKILEVGGSLQDPPGELAVTANSRMSASILLSKLFDDLKCDAERENFHRLCENYIKSWFEGQGLAGKLRAIQTVSCLLQGPCDAGNRALELSGVMESVIALCASEQEEEQLVAVEALIHAAGKAKRASFITANGVSLLKDLYKCSEKDSIRIRALVGLCKLGSAGGTDFSMKQFAEGSTLKLAKQCRKWLCNDQIDAGTRRWAVEGLAYLTFDADVKEEFVEDAAALKALFQLSRLEERSVLFAVASALVNCTNSYDYEEPDPKMVELAKYAKQHVPEQHPKDKPSFVRARVKKLLAAGVVSAMVCMVKTESPVLTSSCRELLSRVFLALVEEVEDRGTVVAQGGGRALIPLALEGTDVGQTKAAQALAKLTITSNPEMTFPGERIYEVVRPLVSLLHLNCSGLQNFEALMALTNLAGISERLRQKILKEKAVPMIEGYMFEEHEMIRRAATECMCNLAMSKEVQDLFEAQGNDRLKLLVLYSGEDDELLQRAAAGGLAMLTSMRPTLCSRIPQVTTHWLEILQALLLSSNQELQHRGAVVVLNMVEASREIASTLMESEMMEILSVLAKGDHSPVTRAAAACLDKAVEYGLIQPNQDGE
-
分子量
129.5 kDa
-
内毒素
< 1.0 EU per μg protein as determined by the LAL method.
-
性状
Freeze-dried powder
-
缓冲液
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
复溶方法
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- 个性化定制
-
稳定性测试
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
保存条件 & 期限
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
运输条件
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
UNC45B is a chaperone protein that plays a crucial role in the proper folding and assembly of specific muscle proteins, particularly in the context of myogenesis and muscle function. It is part of a larger family of UNC45 proteins that are known to assist in the maturation of various myosin isoforms, which are essential for muscle contraction and cellular motility. Abnormalities in UNC45B expression or function have been linked to several muscle-related diseases, including congenital myopathies and heart conditions. The study of UNC45B recombinant protein has gained attention due to its potential applications in therapeutic strategies aimed at correcting these muscular disorders. Researchers have been focusing on the recombinant expression of UNC45B in various systems to analyze its functional properties, interactions with myosins, and its role in muscle cell development. Understanding the molecular mechanisms underlying UNC45B activity could provide insights into the pathogenesis of muscle diseases and pave the way for developing novel interventions. Moreover, recombinant UNC45B can serve as a valuable tool for in vitro studies, allowing scientists to dissect its chaperone activity and identify potential small-molecule inhibitors or activators that could modulate its function in disease contexts. As research progresses, the elucidation of UNC45B's structure-function relationships and its interactions with other myogenic factors will be paramount in advancing our knowledge of muscle biology and enhancing therapeutic approaches for muscle degenerative disorders.
